Dizal (Jiangsu) Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Dizal (Jiangsu) Pharmaceutical has a total shareholder equity of CN¥437.2M and total debt of CN¥819.6M, which brings its debt-to-equity ratio to 187.4%. Its total assets and total liabilities are CN¥1.6B and CN¥1.2B respectively.
Key information
187.4%
Debt to equity ratio
CN¥819.58m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥808.30m |
| Equity | CN¥437.25m |
| Total liabilities | CN¥1.21b |
| Total assets | CN¥1.64b |
Recent financial health updates
Health Check: How Prudently Does Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Use Debt?
Aug 20
Is Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Using Too Much Debt?
Apr 30Recent updates
Financial Position Analysis
Short Term Liabilities: 688192's short term assets (CN¥976.9M) exceed its short term liabilities (CN¥566.9M).
Long Term Liabilities: 688192's short term assets (CN¥976.9M) exceed its long term liabilities (CN¥638.4M).
Debt to Equity History and Analysis
Debt Level: 688192's net debt to equity ratio (2.6%) is considered satisfactory.
Reducing Debt: 688192's debt to equity ratio has increased from 0% to 187.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 688192 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 688192 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.